Abstract 108P
Background
About 70% of patients with colorectal cancer develop liver metastases (LM). Although colorectal cancer patients with resectable LM have a good prognosis, there is little data at the difference in the locations of LM. We investigated how the location of LM affects prognosis of colorectal cancer patients.
Methods
The medical records of 196 colorectal cancer patients with liver metastasis from January 2008 to December 2018 were analyzed retrospectively. We defined liver metastasis within a 3-cm-radius sphere centered on the bifurcation of portal vein by computed tomography as central LM (group C), and other LM outside the 3-cm-radius sphere as peripheral LM (group P). We investigated the relation between location of LM and prognosis by using the Kaplan-Meier method and log-rank test, and the relation between location of LM and resection by using the chi-square test.
Results
Patient characteristics were as follows: median age 68.4 (range 30-87), female/male 115/81, colon/rectal cancer 117/79, advanced/recurrent 150/46, respectively. The characteristics of liver metastasis were as follows: mean maximum tumor size 38 mm (3 - 200), tumor number single/multi 58/138, group C/P 84/112, respectively. Median overall survival (OS) was 31 months [95% confidence interval (CI), 25.5 to 36.5 months] from the date of first diagnosis of LM. We divided 196 patients into two groups ofgroup C (n = 84) and group P (n = 112) by location of LM. Resection rate of LM was 11.9% (group C) and 50.9% (group P). Median OS in group C and group P was 18 months (95% CI, 12.3 to 23.7 months) and 38 months (95% CI, 35.2 to 40.8 months), respectively (p < 0.001). Resection of LM was performed significantly more often in group P than in group C (p < 0.001). Furthermore, the patients with resectable LM had a good prognosis not only in group P (mean OS 135 months, 95% CI, 109.4 to 160.7 months) but also in group C (mean OS 82 months, 95% CI, 67.5 to 96.0 months).
Conclusions
It is suggested that the colorectal cancer patients with peripheral LM might have a better prognosis than the patients with central LM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
358P - Evaluation of continuous low dose versus standard dose capecitabine monotherapy as second/third-line chemotherapy for metastatic malignancies
Presenter: Swaroop Revannasiddaiah
Session: Poster display session
Resources:
Abstract
359P - Factors associated with economic burden among cancer patients with minor children: A cross-sectional web-based survey of an online cancer community
Presenter: Midori Yuki
Session: Poster display session
Resources:
Abstract
360P - Factors influencing treatment decisions among breast cancer patients in the Philippine general hospital cancer institute: Medical oncology outpatient clinic
Presenter: Bobby De Guzman
Session: Poster display session
Resources:
Abstract
361P - The role of volunteers in quality palliative care delivery
Presenter: NABANITA MANDAL
Session: Poster display session
Resources:
Abstract
362P - Survey to assess the efficacy of continuity of care delivered through an out of hours telephonic consultation liaison
Presenter: Rahul D. Arora
Session: Poster display session
Resources:
Abstract
366P - Activity of larotrectinib in TRK fusion cancer patients with primary central nervous system tumours
Presenter: David Ziegler
Session: Poster display session
Resources:
Abstract
367P - Molecular characteristics and efficacy of crizotinib among different subsets of MET Amplification detected by next-generation sequencing in lung cancer
Presenter: Jing Li
Session: Poster display session
Resources:
Abstract
368P - Genomic analysis of malaysian breast cancers unravel molecular differences from Caucasian breast cancers
Presenter: Soo-Hwang Teo
Session: Poster display session
Resources:
Abstract
369P - Institutional-based prospective molecular profiling of advanced solid tumours in Hong Kong: A report of 253 cases
Presenter: Herbert Loong
Session: Poster display session
Resources:
Abstract
370P - Tumour mutation burden analysis in a 5660-cancer-patient cohort reveals cancer type-specific mechanisms for high mutation burden
Presenter: Yuan-Sheng Zang
Session: Poster display session
Resources:
Abstract